Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI608 plus paclitaxel vs placebo plus paclitaxel in advanced gastric or gastroesophageal junction adenocarcinoma
CTR20160293Phase 3Active
- Sponsor
- Biotechnology Company
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of napabucasin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Biotechnology Company. Started Jun 2016; status: active.
02
Drugs
napabucasin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20160293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160293.